胚系DNA修复基因突变与mCRPC患者一线阿比特龙/恩扎卢胺疗效的关系
研究纳入172例开始一线阿比特龙或恩扎卢胺治疗的mCRPC患者,用白细胞DNA检测50个DNA修复基因的胚系致病突变。12%存在任何胚系DNA修复基因突变,5%为BRCA/ATM突变。倾向评分加权多变量分析显示,BRCA/ATM突变者PSA-PFS、PFS和OS更优,但非BRCA/ATM突变者无获益。
要点
- mCRPC患者中胚系DNA修复基因突变占12%,BRCA/ATM突变占5%。
- 胚系BRCA/ATM突变者一线阿比特龙/恩扎卢胺的PSA-PFS、PFS和OS更优。
- 非BRCA/ATM胚系DNA修复基因突变者未见显著获益。
核心结论
- mCRPC患者中胚系BRCA/ATM突变者接受一线阿比特龙或恩扎卢胺的预后优于无突变者。
- 非BRCA/ATM胚系DNA修复基因突变者未显示类似获益。
研究设计与样本
- 研究纳入172例开始一线NHT(阿比特龙或恩扎卢胺)治疗的mCRPC患者。
- 利用白细胞DNA对50个基因进行胚系致病或可能致病突变检测。
主要发现
- 任何胚系DNA修复基因突变见于12%(22/172)的患者,胚系BRCA/ATM突变见于5%(9/172)的患者。
- 未校正分析中,BRCA/ATM突变者PSA-PFS的HR为0.47(p=0.061),PFS的HR为0.50(p=0.090),OS的HR为0.28(p=0.059)。
- 倾向评分加权多变量分析中,BRCA/ATM突变者PSA-PFS的HR为0.48(95%CI 0.25-0.92;p=0.027),PFS的HR为0.52(95%CI 0.28-0.98;p=0.044),OS的HR为0.34(95%CI 0.12-0.99;p=0.048)。
- 非BRCA/ATM胚系突变者所有结局的p值均>0.10。
临床怎么用
- 对mCRPC患者可考虑胚系DNA修复基因检测,尤其关注BRCA/ATM状态以辅助一线NHT疗效预判。
- BRCA/ATM胚系突变者接受一线阿比特龙或恩扎卢胺可能获得更优的PSA-PFS、PFS和OS。
局限性
- BRCA/ATM突变患者数量少(n=9)。
- 结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inherited DNA-repair gene mutations are more prevalent in men with advanced prostate cancer than previously thought, but their clinical implications are not fully understood. OBJECTIVE: To investigate the clinical significance of germline DNA-repair gene alterations in men with metastatic castration-resistant prostate cancer (mCRPC) receiving next-generation hormonal therapy (NHT), with a particular emphasis on BRCA/ATM mutations. DESIGN, SETTING, AND PARTICIPANTS: We interrogated 50 genes for pathogenic or likely pathogenic germline mutations using leukocyte DNA from 172 mCRPC patients beginning treatment with first-line NHT with abiraterone or enzalutamide. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed the impact of germline DNA-repair gene mutation status on ≥50% and ≥90% PSA responses, PSA progression-free survival (PSA-PFS), clinical/radiologic progression-free survival (PFS), and overall survival (OS). Survival outcomes were adjusted using propensity score-weighted multivariable Cox regression analyses. RESULTS AND LIMITATIONS: Among 172 mCRPC patients included, germline mutations (in any DNA-repair gene) were found in 12% (22/172) of men, and germline BRCA/ATM mutations specifically in 5% (9/172) of men. In unadjusted analyses, outcomes to first-line NHT were better in men with germline BRCA/ATM mutations (vs no mutations) with respect to PSA-PFS (hazard ratio [HR] 0.47; p=0.061), PFS (HR 0.50; p=0.090), and OS (HR 0.28; p=0.059). In propensity score-weighted multivariable analyses, outcomes were superior in men with germline BRCA/ATM mutations with respect to PSA-PFS (HR 0.48, 95% confidence interval [CI] 0.25-0.92; p=0.027), PFS (HR 0.52, 95% CI 0.28-0.98; p=0.044), and OS (HR 0.34, 95% CI 0.12-0.99; p=0.048), but not in men with non-BRCA/ATM germline mutations (all p>0.10). These results require prospective validation, and our conclusions are limited by the small number of patients (n=9) with BRCA/ATM mutations. CONCLUSIONS: Outcomes to first-line NHT appear better in mCRPC patients harboring germline BRCA/ATM mutations (vs no mutations), but not for patients with other non-BRCA/ATM germline mutations. PATIENT SUMMARY: Patients with metastatic castration-resistant prostate cancer and harboring germline mutations in BRCA1/2 and ATM benefit from treatment with abiraterone and enzalutamide.
引用
- Antonarakis ES, Lu C, Luber B, et al. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol. 2018. PMID: 29439820. doi:10.1016/j.eururo.2018.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。